Casma Therapeutics Named one of the Boston Business Journal’s Best Places to Work

April 12, 2019

CAMBRIDGE, Mass. – April 12, 2019 – Casma Therapeutics, a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that the company has been named a winner of the Best Places to Work award sponsored by the Boston Business Journal.

The Boston Business Journal’s Best Places to Work awards are designed to honor employers in the greater Boston area who go beyond the norm to foster a supportive, dynamic and meaningful work environment for their employees. Casma was honored in the “extra small” category, which covers companies with fewer than 50 employees.

“The strength of Casma’s science is embedded in the productivity of our team,” said Keith Dionne, Casma’s chief executive officer. “In the year since our launch, we have made it a top priority to ensure Casma is a nurturing, fun and invigorating place to work. This award is testament to those efforts, and we are delighted to be selected.”

The Boston Business Journal will recognize this year’s 79 honorees at an awards ceremony on June 19 at the World Trade Center in Boston. Honorees will also be featured in a special June 21 edition of the Boston Business Journal.


About Casma Therapeutics

Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy-lysosome system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications. Casma was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit



Ten Bridge Communications
Stephanie Simon, 617-581-9333

Back to news & media

Keep reading: